Friday, 17 Nov 2017

You are here

Pharma Pays $8.2 Billion to Physicians in 2016

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

While research expenditures ($4.36 billion) made up more than half of this amount, the remainder includes funds distributed to cover expenses like travel, gifts, speaking fees and meals ($2.8 billion in "general payments"). 

The top three payouts came from Roche ($586 million), Novartis and Pfizer ($475 million each). Novartis, Pfizer and AstraZeneca spent the most on research payments ($450 million, $430 million, $367 million, respectively).

The detailed data also highlights the complexity of multinational drug companies' corporate structures. Pfizer, for instance, reported payments made through 14 different corporate entities. J&J and Roche each had more than ten reporting bodies, if the wholly owned subsidiaries of Janssen and Genentech, respectively, are included. 

For more info on open payments or payments made to individual physicians go to: https://openpaymentsdata.cms.gov/summary.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

While these numbers are somewhat alarming and reflect speaker fees, consultant fees and meals, I wonder if they also include payment for services performed in clinical trials. Physicians work hard in clinical research and deserve fair reimbursement. I am aware that early on the Sunshine Act inappropriately posted these numbers. Of course payments often go to salary for study coordinators, IRB, etc and do not end up entirely in the physicians pocket book.

More Like This

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Podcast of ACR17 - Day 4

Care to learn what you missed at last weeks ACR 2017 meeting in San Diego?  Here are 4 one hour audio podcasts - each with a compliation of 2-4 minute reports from Drs. Cush, Kavanaugh, the RheumNow Faculty and other rheumatology thought leaders and researchers.  Another good way to learn from RheumNow.

The ACR17 RheumNow Week in Review - 10 November 2017

This special edition of the RheumNow Week in Review covers highlights of selected sessions from the 2017 ACR annual meeting in San Diego. Dr. Jack Cush reviews lupus and the microbiome, daily podcasts, pregnancy and lactation, osteoporosis drug holidays and screening for pulmonary hypertension.

Many thanks to the RheumNow Faculty for their work and expertise!

Podcast of ACR 17 - Day 3

Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !

ACR 2017 - Day 3 and 4 Highlights

Day 3 at the annual meeting was rich with information. Yet the most anticipated and best attended session was the Late Breaking Abstracts and the session revealing the new ACR/NPF Guidelines for Psoriatic Arthritis (more on the latter in another report).  Day 4 was full of review sessions and a modicum of original content and for me, the 7:30AM Rheumatology Roundup.